Biomaterial Database

L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients. 1989

M Yoshida, and S Noguchi, and S Kuramoto

L-threo-3,4-dihydroxyphenylserine (L-DOPS) was administered to six parkinsonian patients for the treatment of gait related akinesia which was refractile to L-DOPA treatment. One responded with marked improvement and one with only mild improvement. Although number of patients who respond markedly to this noradrenaline precursor, L-DOPS, is limited, L-DOPS was felt to be the most effective treatment modality for L-DOPA refractile gait related akinesia and L-DOPA related orthostatic hypotension.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010300	Parkinson Disease	A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004334	Drug Administration Schedule	Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.	Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260	Female		Females
D005684	Gait	Manner or style of walking.	Gaits
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D001072	Apraxias	A group of cognitive disorders characterized by the inability to perform previously learned skills that cannot be attributed to deficits of motor or sensory function. The two major subtypes of this condition are ideomotor (see APRAXIA, IDEOMOTOR) and ideational apraxia, which refers to loss of the ability to mentally formulate the processes involved with performing an action. For example, dressing apraxia may result from an inability to mentally formulate the act of placing clothes on the body. Apraxias are generally associated with lesions of the dominant PARIETAL LOBE and supramarginal gyrus. (From Adams et al., Principles of Neurology, 6th ed, pp56-7)	Dressing Apraxia,Dyspraxia,Ideational Apraxia,Apraxia,Apraxia of Phonation,Apraxia, Articulatory,Apraxia, Developmental Verbal,Apraxia, Facial-Oral,Apraxia, Gestural,Apraxia, Motor,Apraxia, Oral,Apraxia, Verbal,Developmental Verbal Dyspraxia,Dyspraxia, Articulatory,Dyspraxia, Oral,Dyspraxia, Verbal,Speech And Language Disorder With Orofacial Dyspraxia,Speech-Language Disorder 1,1s, Speech-Language Disorder,Apraxia, Dressing,Apraxia, Facial Oral,Apraxia, Ideational,Apraxias, Articulatory,Apraxias, Developmental Verbal,Apraxias, Dressing,Apraxias, Facial-Oral,Apraxias, Gestural,Apraxias, Ideational,Apraxias, Motor,Apraxias, Oral,Apraxias, Verbal,Articulatory Apraxia,Articulatory Apraxias,Articulatory Dyspraxia,Articulatory Dyspraxias,Developmental Verbal Apraxia,Developmental Verbal Apraxias,Developmental Verbal Dyspraxias,Disorder 1, Speech-Language,Disorder 1s, Speech-Language,Dressing Apraxias,Dyspraxia, Developmental Verbal,Dyspraxias,Dyspraxias, Articulatory,Dyspraxias, Developmental Verbal,Dyspraxias, Oral,Dyspraxias, Verbal,Facial-Oral Apraxia,Facial-Oral Apraxias,Gestural Apraxia,Gestural Apraxias,Ideational Apraxias,Motor Apraxia,Motor Apraxias,Oral Apraxia,Oral Apraxias,Oral Dyspraxia,Oral Dyspraxias,Phonation Apraxia,Phonation Apraxias,Speech Language Disorder 1,Speech-Language Disorder 1s,Verbal Apraxia,Verbal Apraxia, Developmental,Verbal Apraxias,Verbal Apraxias, Developmental,Verbal Dyspraxia,Verbal Dyspraxia, Developmental,Verbal Dyspraxias,Verbal Dyspraxias, Developmental

Related Publications

M Yoshida, and S Noguchi, and S Kuramoto

Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine.

January 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

M Yoshida, and S Noguchi, and S Kuramoto

Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.

March 1990, Japanese journal of pharmacology,

M Yoshida, and S Noguchi, and S Kuramoto

Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats.

December 1981, The Journal of pharmacy and pharmacology,

M Yoshida, and S Noguchi, and S Kuramoto

Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.

November 1984, Neurology,

M Yoshida, and S Noguchi, and S Kuramoto

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.

January 1993, Journal of neural transmission. Parkinson's disease and dementia section,